Clinical analysis of immune liver injury induced by camrelizumab
Objective To investigate the case characteristics of immune liver injury induced by camrelizumab,and to provide reference for clinical safety of drug use.Methods According to keywords,the case reports of immune liver injury induced by camrelizumab published from the establishment of the database to August 2023 were retrieved and screened,and the data were extracted and analyzed.Results A total of 12 literatures were selected,involving 12 patients,including 7 males and 5 females.Among them,age 43-76 years old,the average age was(62.92±10.19)years old,and most of them developed immune liver injury within 1 month.The primary diseases were all malignant tumors,and the main dosage of camrelizumab was 200mg intravenously,once every 3 weeks;The main immune liver injury was grade 3.After drug withdrawal and corresponding symptomatic treatment,the symptoms improved in 3 cases(25.00%),recovered in 5 cases(41.67%),and did not recover in 4 cases(33.33%).Conclusion Camrelizumab can cause immune liver injury,which can lead to death in severe cases.Therefore,clinical rational use of camrelizumab should be strengthened,the awareness of immune-related adverse events should be improved and pay attention to the immunological liver injury caused by camrelizumab.
国家科技期刊平台
NSTL
万方数据
